Zacks: Brokerages Expect Agilent Technologies Inc (A) Will Post Quarterly Sales of $1.27 Billion

Analysts expect Agilent Technologies Inc (NYSE:A) to report sales of $1.27 billion for the current quarter, Zacks Investment Research reports. Six analysts have made estimates for Agilent Technologies’ earnings, with the highest sales estimate coming in at $1.27 billion and the lowest estimate coming in at $1.26 billion. Agilent Technologies reported sales of $1.21 billion in the same quarter last year, which would suggest a positive year-over-year growth rate of 5%. The firm is expected to report its next quarterly earnings report on Monday, May 13th.

According to Zacks, analysts expect that Agilent Technologies will report full year sales of $5.18 billion for the current fiscal year, with estimates ranging from $5.17 billion to $5.19 billion. For the next financial year, analysts expect that the company will post sales of $5.49 billion, with estimates ranging from $5.45 billion to $5.52 billion. Zacks’ sales calculations are an average based on a survey of sell-side research firms that cover Agilent Technologies.

Agilent Technologies (NYSE:A) last posted its earnings results on Wednesday, February 20th. The medical research company reported $0.76 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.73 by $0.03. The firm had revenue of $1.28 billion for the quarter, compared to the consensus estimate of $1.27 billion. Agilent Technologies had a net margin of 22.86% and a return on equity of 19.90%. The business’s quarterly revenue was up 6.0% on a year-over-year basis. During the same period in the prior year, the business posted $0.66 earnings per share.



A has been the topic of several analyst reports. Alembic Global Advisors downgraded shares of Agilent Technologies to a “hold” rating in a research report on Monday, December 31st. Needham & Company LLC assumed coverage on Agilent Technologies in a research report on Wednesday, January 2nd. They issued a “buy” rating and a $77.00 target price for the company. Zacks Investment Research upgraded Agilent Technologies from a “hold” rating to a “buy” rating and set a $79.00 target price for the company in a research report on Monday, January 21st. Deutsche Bank upped their target price on Agilent Technologies from $80.00 to $85.00 and gave the stock a “buy” rating in a research report on Tuesday, February 12th. Finally, Robert W. Baird reiterated a “buy” rating and set a $82.00 price objective (up previously from $77.00) on shares of Agilent Technologies in a research report on Wednesday, February 20th. Two investment analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $87.17.

In other news, Director Paul N. Clark sold 2,823 shares of the stock in a transaction on Wednesday, March 27th. The stock was sold at an average price of $80.31, for a total value of $226,715.13. Following the completion of the sale, the director now owns 88,857 shares in the company, valued at $7,136,105.67. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Michael Tang sold 6,728 shares of the stock in a transaction on Wednesday, March 27th. The shares were sold at an average price of $80.50, for a total value of $541,604.00. The disclosure for this sale can be found here. Insiders have sold a total of 83,722 shares of company stock valued at $6,532,504 in the last quarter.

Several institutional investors and hedge funds have recently added to or reduced their stakes in A. Captrust Financial Advisors increased its stake in shares of Agilent Technologies by 2,121.1% in the fourth quarter. Captrust Financial Advisors now owns 422 shares of the medical research company’s stock worth $29,000 after acquiring an additional 403 shares during the last quarter. Lake Point Wealth Management acquired a new position in shares of Agilent Technologies in the fourth quarter worth $30,000. JOYN Advisors Inc. increased its stake in shares of Agilent Technologies by 186.6% in the fourth quarter. JOYN Advisors Inc. now owns 470 shares of the medical research company’s stock worth $32,000 after acquiring an additional 306 shares during the last quarter. We Are One Seven LLC acquired a new position in shares of Agilent Technologies in the fourth quarter worth $33,000. Finally, Truehand Inc acquired a new position in shares of Agilent Technologies in the fourth quarter worth $33,000.

Agilent Technologies stock traded down $0.72 during mid-day trading on Friday, hitting $80.26. 82,990 shares of the company’s stock were exchanged, compared to its average volume of 1,431,017. The company has a debt-to-equity ratio of 0.36, a current ratio of 3.39 and a quick ratio of 2.79. The company has a market capitalization of $25.71 billion, a price-to-earnings ratio of 28.75, a PEG ratio of 2.25 and a beta of 1.38. Agilent Technologies has a 1-year low of $60.42 and a 1-year high of $82.27.

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 24th. Stockholders of record on Tuesday, April 2nd will be given a dividend of $0.164 per share. The ex-dividend date is Monday, April 1st. This represents a $0.66 dividend on an annualized basis and a dividend yield of 0.82%. Agilent Technologies’s dividend payout ratio (DPR) is presently 23.66%.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. It operates through three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; laboratory software and information management and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps; and measurement technologies.

Featured Story: Book Value Per Share – BVPS

Get a free copy of the Zacks research report on Agilent Technologies (A)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Agilent Technologies (NYSE:A)

Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.